Clinical effect observation of teneplase in the adjuvant treatment of acute lower extremity deep vein thrombosis with catheter-directed thrombolysis

Tian Zhong; Yuan Fukang; Tian Zhilong

doi:10.3760/j.issn.1673-4777.2024.09.019

Abstract：Objective To observe the clinical effect of teneplase in the adjuvant treatment of acute lower extremity deep vein thrombosis(DVT)with catheter-directed thrombolysis(CDT).Methods A retrospective analysis was conducted on the clinical data of 104 patients with acute lower extremity DVT admitted to the Department of Vascular Surgery,Xuzhou Central Hospital from January 2022 to June 2023.Patients were classified into the combination group(50 cases)and the urokinase group(54 cases)based on different therapies.Postoperative venous patency score,venous patency rate,limb swelling reduction rate,thrombus clearance grade,urokinase dosage,thrombolysis time,hospital stay,and complications in two groups of patients were compared.Results The postoperative venous patency score of the combined group was lower than that of the urokinase group,and the postoperative venous patency rate and limb swelling reduction rate were both higher than those of the urokinase group[(1.6±1.0)vs(2.3±1.1),(79±13)％vs(68±15)％,(73±12)％vs(66±8)％],with statisti-cally significant differences(all P＜0.05).There was no statistically significant difference in thrombus clearance grading between the two groups(P＞0.05).The dosage of urokinase,thrombolysis time,and hospital stay of patients in the combination group were less/shorter than those in the urokinase group,and the differences were statistically significant(all P＜0.05).There was no statistically significant difference in the incidence of postoper-ative in two groups(P＞0.05).Conclusions Compared with the use of urokinase alone,the use of teneplase assisted urokinase for CDT treatment of acute lower extremity DVT can reduce the amount of urokinase dosage,and shorten thrombolysis time and hospital stay.The recent thrombolysis effect is certain and the operation is simple.